Company Profile

Kosan Biosciences Inc
Profile last edited on: 4/22/2019      CAGE: 46V22      UEI: V533BCS95KV6

Business Identifier: Drug discovery and development of compounds from a class of natural products known as polyketides
Year Founded
1995
First Award
1996
Latest Award
2006
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3832 Bay Center Place
Hayward, CA 94545
   (510) 732-8400
   N/A
   www.kosan.com
Location: Single
Congr. District: 15
County: Alameda

Public Profile

In June 2008, Kosan Biosciences Inc was acquired by Bristol-Myers Squibb Company. Very active in SBIR, Kosan Biosciences Incorporated had been a biotechnology company using its proprietary technologies to develop drug candidates from a class of natural product compounds known as polyketides. Polyketides are naturally made in very small amounts in certain microorganisms and are difficult to make or modify chemically. Using its proprietary technologies, the Company was able to create, modify and produce polyketides in ways that chemists generally cannot. Because polyketides have been a rich source of marketed drugs, creating novel polyketides is expected to provide the Company with a pipeline of potential drug candidates that address existing or potential large markets. Kosan has clinical trials of its lead anti-cancer compound, Epothilone D, in cancer patients with advanced solid tumors.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : KOSN
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 2 NIH $475,000
Project Title: Combinatorial Biosynthesis of Polyketides
2005 2 NIH $1,358,744
Project Title: New Ketolide Antibacterial Drugs
2005 2 NIH $850,000
Project Title: Novel Geldanamycin Analogs as Anti-tumor Agents
2005 2 NIH $600,000
Project Title: Leptomycin B Analogs
2005 1 NIH $100,000
Project Title: Ambruticin for Aspergillus

Key People / Management

  Michael Ostrach -- President

  Daniel V Santi -- President

  Mary C Betlach

  Thomas C Bruice

  Christopher W Carreras

  Steven D Dong

  Hugo C Gramajo

  Peter A Hevezi

  CR Hutchinson

  Leonard Katz

  Robert N McDaniel

  Brian W Metcalf

  David C Myles

  Christopher D Reeves

  W P Revill

  George P Smith

  Rainer A E Ziermann

Company News

There are no news available.